Reviews and reports
- Salt reduction is beneficial for people with Type 2 diabetes
- Pioglitazone raises risk of bladder cancer by 63%
- Diabetes 2015 – Care in Crisis
- Diabetic Retinopathy
- People with diabetes not offered dietary advice
- Medication errors in hospitals
- First ever mandatory care standards to improve the level of care of children and young people with diabetes
- Insulin Analogues and Cancer – A Possible Link That Needs Further Investigation
- The Safety of Insulin Analogues – should patients be concerned?
- Bellagio Report
- Health Select Committee – IDDT gives evidence
- Warnings about ‘human’ insulin from the manufactuers, Novo Nordisk and Aventis
- Zyban – Safety precautions from the Committee on Safety of Medicines
- Novo Nordisk discontinue some GM ‘human’ insulins
- IQWiG: No proof long-acting insulin analogues outperform human insulin for Type 2 diabetes
- Cochrane Review – long-acting analogues vs NPH insulin in Type 2 diabetes
- IQWiG: Short-acting insulin analogues are not superior to regular ‘human’ insulin in Type 2 diabetes
- IQWiG: Rapid-acting analogues are not superior to ‘human’ insulin for Type 1 diabetes
- About IQWiG
- Cochrane review of short-acting insulin analogues versus regular human insulin in patients with diabetes mellitus
- Cochrane review of ‘human’ vs animal insulin
- About Cochrane Reviews
- Insulin – A Voice for Choice By Arthur Teuscher
Novo Nordisk discontinue some GM ‘human’ insulins
June 29th 2005
‘Human’ Actrapid no longer available in cartridges for pens [from October 2005]
Novo Nordisk brought forward the discontinuation of some GM ‘human’ insulins to October 2005. However, by 2009, the discontinuation of ‘human’ insulin that concerns most people is ‘human’ Actrapid in cartridges for pens. This means that people who want to continue to use ‘human’ Actrapid are being ‘forced’ to use a 10ml vial and syringe.
Of course, the Novo Nordisk recommended alternative is that people change to the newer short-acting insulin analogue, NovoRapid. Under these circumstances, changing your insulin is not being done clinical reasons to benefit you but because Novo Nordisk has made yet another commercial decision and it is this commercial decision which is dictating your treatment – something that must be deplored!
There are alternatives, you do not have to change to insulin analogues
If you do not want to change to GM analogue insulins but want to continue using pens for injection, then there are alternatives from other manufacturers. You should discuss with your doctor or health professional. The alternatives are:
- Humulin S made by Eli Lilly – a human insulin available in cartridges.
- Hypurin Porcine Neutral made by Wockhardt UK under the name of CP Pharmaceuticals – a short-acting natural pork insulin available in cartridges.
Changing insulin therapy
Novo Nordisk state that ‘any change of insulin therapy should be carried out by a suitably experienced healthcare professional’ . This is particularly so when changing to insulin analogues because they have a different speed of onset, peak of action and different duration of action from both ‘human’ and animal insulins.